Madison Dearborn signed definitive agreement for majority ownership of Ikaria in transaction valued ~$1.6B; included separation of Ikaria's outpatient pipeline as spin-out to existing shareholders.
Did it work? Outcome assessment
Strategic verdict
Achieved Stated Rationale
Financial impact
Accretive
Pipeline outcome
Mixed
Assessment window: 10yr post-close.
Key facts
AnnouncedDec 24, 2013
ClosedFeb 12, 2014
Deal value$1.6B
Deal typeTake-Private
Therapeutic areaHypoxic respiratory failure in term/near-term newborns
IndicationsHypoxic respiratory failure in term/near-term newborns